1-5 of 5
Abraham M Varghese
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Praveen Kaudlay, MBBS, MRCP, Haiying Hua, MD, Guansheng He, MD, Darren J Newton, PhD, Abraham M Varghese, MB ChB, Talha Munir, MBBS, MRCP, FRCPath, Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Stephen John Richards, PhD, Peter Hillmen, MB ChB, PhD
Journal: Blood
Blood (2013) 122 (21): 2466.
https://doi.org/10.1182/blood.V122.21.2466.2466
Published: 2013
Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc
Journal: Blood
Blood (2013) 122 (21): 1639.
https://doi.org/10.1182/blood.V122.21.1639.1639
Published: 2013
Journal Articles

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Abraham M Varghese, Andy Rawstron, PhD, Gina M Doody, PhD, Darren J Newton, Reuben Tooze, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2012) 120 (21): 3899.
https://doi.org/10.1182/blood.V120.21.3899.3899
Published: 2012
Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 60.
https://doi.org/10.1182/blood.V116.21.60.60
Published: 2010
Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 922.
https://doi.org/10.1182/blood.V116.21.922.922
Published: 2010